Literature DB >> 8599446

Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma.

K A Collins1, W L White.   

Abstract

The expression of intercellular adhesion molecule 1 (ICAM-1), a molecule pivotal in many inflammatory and immune paracrine interactions, has been highly correlated with malignant melanoma (MM) progression. Because numerous parallels exist between tissues of neural crest origin and the immune system in the regulation of postmitotic cell survival, ICAM-1 expression was studied in MM and compared with that of B-cell lymphoma/leukemia 2 protein (bcl-2 oncoprotein), an important regulator in prolonging lymphoid cell survival by blocking programmed cell death. Frozen sections from 33 cases were studied by immunoperoxidase techniques: 14 primary MM (five in situ), nine metastatic MM (one epidermotropic), four melanocytic nevi, and six normal skin controls. The percentages of the cells that stained and their intensities (0-4+) were graded. Both ICAM-1 (90%, 3-4+) and bcl-2 (95%, 2-4+) were strongly expressed in all nine metastases, including the epidermotropic disease extension. Bcl-2 strongly decorated the tumor cells in all 14 cases of primary MM (80%, 2-4+); in the five in situ MM, bcl-2 stained the atypical melanocytes at the dermal-epidermal junction (DEJ) and throughout the epidermis (75%, 1-2+). In contrast, ICAM-1 was negative in the in situ MM. ICAM-1 expression became strong (85%, 2-4+) in the dermal component of early invasive disease. Both ICAM-1 and bcl-2 were expressed in melanocytic nevi, decreasing in intensity deep within the dermis as the nevus cells senesced ("matured"). Only bcl-2 was expressed in the normal melanocytes of the six skin controls. These data show that bcl-2 is constitutively expressed in normal melanocytes and melanocytic nevi and persists in the transformed cells of early and late MM. ICAM-1 is expressed only after dermal involvement occurs, both in melanocytic nevi and in invasive MM; it persists in metastatic disease. The coexpression of bcl-2 and ICAM-1 demonstrates another similarity between the immune and neural crest systems, but it does not define or necessarily imply any functional interaction between the two proteins. The intercellular relationship of these two molecules, if any, remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8599446     DOI: 10.1097/00000372-199510000-00001

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  6 in total

1.  Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy.

Authors:  A Porgador; O Mandelboim; N P Restifo; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

2.  The role of Bcl-2 family members in the progression of cutaneous melanoma.

Authors:  Jason A Bush; Gang Li
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

3.  Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias.

Authors:  Anneli R Bowen; Adrianne N Hanks; Kelley J Murphy; Scott R Florell; Douglas Grossman
Journal:  Am J Dermatopathol       Date:  2004-06       Impact factor: 1.533

4.  Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment.

Authors:  Rina A Anvekar; James J Asciolla; Derek J Missert; Jerry E Chipuk
Journal:  Front Oncol       Date:  2011-10-13       Impact factor: 6.244

5.  Bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: a historical cohort study.

Authors:  Marília B Espíndola; Oly C Corleta
Journal:  World J Surg Oncol       Date:  2008-06-20       Impact factor: 2.754

6.  Kaposi's Sarcoma-Associated Herpesvirus Subversion of the Anti-Inflammatory Response in Human Skin Cells Reveals Correlates of Latency and Disease Pathogenesis.

Authors:  Judith M Fontana; Justin G Mygatt; Katelyn L Conant; Chris H Parsons; Johnan A R Kaleeba
Journal:  J Skin Cancer       Date:  2014-02-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.